v3.26.1
Revenue Recognition - Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) [Line Items]          
Revenue $ 4,022,763 $ 983,318 $ 6,662,116 $ 2,347,859  
Cost of revenue 1,444,592 $ 397,686 2,317,454 $ 818,133  
Gross profit     $ 4,344,662    
Gross Profit %     65.21%    
Assets 5,850,003   $ 5,850,003   $ 4,488,694
Net profit (loss)     (3,215,926)    
Global Stem Cells Group [Member]          
Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) [Line Items]          
Revenue     6,662,116    
Cost of revenue     2,317,454    
Gross profit     $ 4,344,662    
Gross Profit %     65.21%    
Assets 4,008,924   $ 4,008,924    
Net profit (loss)     621,595    
Regenerative Medical Technology Group [Member]          
Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) [Line Items]          
Revenue        
Cost of revenue        
Gross profit        
Gross Profit %     0.00%    
Assets $ 1,841,079   $ 1,841,079    
Net profit (loss)     $ (3,837,520)